161 related articles for article (PubMed ID: 21311486)
1. [Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis].
Petrova LV; Boĭko AN; Batysheva TT; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):41-5. PubMed ID: 21311486
[TBL] [Abstract][Full Text] [Related]
2. Extended use of glatiramer acetate (Copaxone) for MS.
Greenstein JI
Neurology; 1999 Mar; 52(4):897-8. PubMed ID: 10078765
[No Abstract] [Full Text] [Related]
3. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone.
Charach G; Grosskopf I; Weintraub M
Digestion; 2008; 77(3-4):198-200. PubMed ID: 18607107
[TBL] [Abstract][Full Text] [Related]
4. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS
Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
[TBL] [Abstract][Full Text] [Related]
5. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
Rotondi M; Bergamaschi R; Chiovato L
Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
[No Abstract] [Full Text] [Related]
6. CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with Glatiramer Acetate (Copaxone).
Losy J; Michałowska-Wender G; Kurdyńska A; Wender M
Folia Neuropathol; 2005; 43(3):153-5. PubMed ID: 16245210
[TBL] [Abstract][Full Text] [Related]
7. [A possible effect of the immunomodulating therapy with beta-interferons and glatimer acetate on the development of thyroid disease in patients with multiple sclerosis].
Petrova LV; Boĭkova AN; Batysheva TT; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):58-67. PubMed ID: 21916158
[TBL] [Abstract][Full Text] [Related]
8. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of glatiramer acetate in clinical practice: an observational study.
Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
[TBL] [Abstract][Full Text] [Related]
10. [A place of first-line drugs in treatment of multiple sclerosis].
Kasatkin DS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(12):145-151. PubMed ID: 28635741
[TBL] [Abstract][Full Text] [Related]
11. [Pathology of the thyroid gland and multiple sclerosis: a possible influence on efficacy and tolerability of treatment].
Bagir' LV; Batysheva TT; Boĭko AN; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):10-5. PubMed ID: 19156080
[TBL] [Abstract][Full Text] [Related]
12. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
[TBL] [Abstract][Full Text] [Related]
13. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation.
Fragoso YD
Expert Opin Drug Saf; 2014 Dec; 13(12):1743-8. PubMed ID: 25176273
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].
Boĭko AN; Davydovskaia MV; Demina TL; Lashch NIu; Ovcharov VV; Popova EV; Popova NF; Romashkin AV; Boĭko OV; Khachanova NV; Sharanova SN; Shchur SG; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):86-92. PubMed ID: 22677683
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate (Copaxone) therapy for multiple sclerosis.
Dhib-Jalbut S
Pharmacol Ther; 2003 May; 98(2):245-55. PubMed ID: 12725872
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Fragoso YD; Finkelsztejn A; Kaimen-Maciel DR; Grzesiuk AK; Gallina AS; Lopes J; Morales NM; Alves-Leon SV; de Almeida SM
CNS Drugs; 2010 Nov; 24(11):969-76. PubMed ID: 20806993
[TBL] [Abstract][Full Text] [Related]
18. [3-year results of clinical and immunological monitoring of patients with multiple sclerosis treated by copaxone].
Orlova IuIu; Alifirova VM; Cherdyntseva NV; Zagrebina IA; Bychkova IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(5):23-7. PubMed ID: 15952536
[TBL] [Abstract][Full Text] [Related]
19. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate.
Frese A; Bethke F; Lüdemann P; Stögbauer F
J Neurol; 2000 Sep; 247(9):713. PubMed ID: 11081814
[No Abstract] [Full Text] [Related]
20. Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months.
Fiore AP; Fragoso YD
Arq Neuropsiquiatr; 2005 Sep; 63(3B):738-40. PubMed ID: 16258646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
